Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for an audio catch-up on the latest key developments in the worldwide biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things. 

This episode includes insights from around the biopharma world for the business week ended 5 February 2021.

This time we have views on, and progress with, Pfizer Inc. and Johnson & Johnson’s coronavirus vaccines, a delay for a closely-watched Alzheimer’s drug, an interview with senior Amgen, Inc. executives, and more industry insiders' comments on key topics in the latest in the Scrip Asks series. 

These and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and now on Spotify Podcasts - and also via smart speakers if one of these channels has been set up as your default podcast provider. 

Stories mentioned in this episode:

(Also see "COVID-19 Windfall Will Help Pfizer Remain Top Drug Company" - Scrip, 2 Feb, 2021.)

(Also see "J&J’s One-Shot Vaccine Shows 66% Efficacy, But Company Says There’s More To It" - Scrip, 29 Jan, 2021.)

(Also see "Aducanumab Approval Decision Delayed: Could This Be Good News?" - Scrip, 29 Jan, 2021.)

(Also see "While Amgen Sees Success For Two Growth Drivers, Headwinds Remain" - Scrip, 1 Feb, 2021.)

(Also see "Scrip Asks…What Does 2021 Hold For Biopharma? Part 3: Patient Access To Health Care" - Scrip, 29 Jan, 2021.)


Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts